Hakes T B, Dougherty J B, Raymond V
Am J Clin Oncol. 1986 Jun;9(3):262-3. doi: 10.1097/00000421-198606000-00016.
Idarubicin, an anthracycline analogue, was studied in a Phase II trial of 18 patients with advanced cervical carcinoma. Fourteen patients had received no prior chemotherapy (11 had received radiotherapy and three were untreated). All patients received at least two courses of idarubicin at a dose of 12.5 mg/m2 i.v. every 3 weeks. No responses were noted. Fifteen patients had uninterrupted progression of disease and three were stable for 4, 5, and 6 months respectively. Myelosuppression was the most common side effect. Idarubicin displayed no antitumor effect in 18 minimally pretreated cervical carcinoma patients.
伊达比星，一种蒽环类类似物，在一项针对18例晚期宫颈癌患者的II期试验中进行了研究。14例患者之前未接受过化疗（11例接受过放疗，3例未接受过任何治疗）。所有患者均接受了至少两个疗程的伊达比星治疗，剂量为12.5mg/m²，静脉注射，每3周一次。未观察到任何缓解情况。15例患者病情持续进展，3例患者分别稳定了4个月、5个月和6个月。骨髓抑制是最常见的副作用。伊达比星在18例预处理最少的宫颈癌患者中未显示出抗肿瘤作用。
